Complicated Skin And Skin Structure Infections Drugs Market Analysis, Size, Share, Trends And Forecast 2033

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Complicated Skin And Skin Structure Infections Drugs Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $13.78 billion In 2028 At A CAGR Of 9.7% :

The complicated skin and skin structure infections drugs market size has grown rapidly in recent years. It will grow from $8.55 billion in 2023 to $9.51 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to infectious disease prevalence, increase in hospital-acquired infections, prevalence of complicated skin and skin structure infections, growing demand for effective treatment options, rising disposable incomes.

The complicated skin and skin structure infections drugs market size is expected to see strong growth in the next few years. It will grow to $13.78 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to increasing healthcare expenditure, increasing investment in r&d activities, rising demand for novel antibiotics, increasing incidence of antibiotic-resistant infections, growing demand for personalized medicine. Major trends in the forecast period include advancements in wound care products, targeted antibiotics, digital health monitoring, natural and alternative remedies, global collaborations.

Request A Sample Of This Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12940&type=smp

Complicated Skin And Skin Structure Infections Drugs Market Major Segments
The complicated skin and skin structure infections drugs market covered in this report is segmented -
1) By Active Ingredients: Delafloxacin; Vancomycin; Ceftaroline Fosamil; Linezolid; Other Active Ingredients
2) By Route of Administration: Oral; Topical; Parenteral
3) By End User: Hospitals; Homecare; Specialty Clinics; Other End-Users

Key Driver - Rising Skin Disease Prevalence Fueling Growth In Complicated Skin And Skin Structure Infections Drugs Market

The increasing prevalence of skin disease is expected to propel the growth of the complicated skin and skin structure infections drugs market going forward. Skin diseases are medical conditions that affect the skin's appearance, structure and function. These conditions can involve the skin, hair, nails and related tissues. Various antibiotic drugs are used to treat resistant bacteria in cSSSI. Thus, the rise in skin disease cases can lead to new cSSSI drug approvals, raise awareness and promote early diagnosis of complicated skin and skin structure infections. For instance, in April 2022, according to the American Academy of Dermatology Association, a US-based non-profit medical specialty association, approximately 9,500 people in the US will be diagnosed with skin cancer daily. Furthermore, in March 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, the total number of deaths from fungal infections increased from 5,922 in 2020 to 7,199 in 2021. Therefore, the increasing prevalence of skin disease drives the growth of the complicated skin and skin structure infections drugs market.

Customise This Report As Per Your Requirements -
https://www.thebusinessresearchcompany.com/Customise?id=12940&type=smp

Prominent Trend - Evolving Treatment Landscape To Gain A Competitive Edge

Major companies operating in the complicated skin and skin structure infections drugs market are developing innovative products, such as Xydalba, to gain a competitive edge in the market. For instance, in January 2022, Paladin Labs Inc., a Canada-based pharmaceutical company and a subsidiary of Endo International PLC, launched Xydalba (dalbavancin for injection) in Canada, an intravenous therapy that treats acute bacterial skin and skin structure infections (ABSSSI) in adults and children aged three months and older. Xydalba is a second-generation semi-synthetic lipoglycopeptide antibiotic that interferes with forming bacterial cell walls, effectively killing the bacteria. It is effective against many gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). ABSSSI (Acute Bacterial Skin and Skin Structure Infections) is a subset or a specific classification of complicated skin and skin structure infections (cSSSI).

Complicated Skin And Skin Structure Infections Drugs Market Players
Major players in the complicated skin and skin structure infections drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Merck & Co. Inc., AstraZeneca PLC, Abbott Laboratories, Sanofi SA, GlaxoSmithKline PLC, Eli Lilly and Company, Cipla Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi, Macleods Pharmaceuticals, Sun Pharmaceutical Industries Limited, Dr Reddy's Laboratories Ltd., Lupin Pharmaceuticals, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, LEO Pharma, Wockhardt, Paratek Pharmaceuticals, Basilea Pharmaceutica AG, Melinta Therapeutics Inc., Nabriva Therapeutics AG, MerLion Pharmaceuticals GmbH.

View The Full Report Here -
https://www.thebusinessresearchcompany.com/report/complicated-skin-and-skin-structure-infections-drugs-global-market-report

Largest And Fastest Growing Region In The Market
Asia-Pacific was the largest region in the complicated skin and skin structure infections drugs market in 2023. The regions covered in complicated skin and skin structure infections drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Complicated Skin And Skin Structure Infections Drugs Market Report Structure
3. Complicated Skin And Skin Structure Infections Drugs Market Trends And Strategies
4. Complicated Skin And Skin Structure Infections Drugs Market - Macro Economic Scenario
5. Complicated Skin And Skin Structure Infections Drugs Market Size And Growth
…..
27. Complicated Skin And Skin Structure Infections Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.